PURPOSE: Combining anthracyclines and taxanes are to date the most active cytotoxic treatment option in the neoadjuvant and palliative therapy of breast cancer patients. Adding trastuzumab to these cytotoxic agents can improve outcome for women with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. We conducted a pilot study of preoperative epidoxorubicin and docetaxel plus trastuzumab in outpatient patients suffering from breast cancer. PATIENTS AND METHODS: Fourteen consecutive patients were enrolled in this prospective clinical pilot trial. Preoperative treatment consisted of weekly trastuzumab (4 mg/kg body-weight loading dose, 2 mg/kg/week maintenance dose), in combination with weekly epidoxorubicin (30 mg/m2 body surface area [BSA]) and docetaxel (35 mg/m2 BSA) once a week for 6 weeks followed by 1 week off therapy. RESULTS: Patients received a total of 30 cycles (median: 2 cycles, range: 2-3 cycles) of this therapeutic regimen. Outpatient epidoxorubicin and docetaxel plus trastuzumab were well tolerated. A major response to this preoperative therapy regimen could be demonstrated in 12 of 14 patients (86%) leading to breast-conserving surgery in 11 of 14 patients (79%). CONCLUSIONS: We conclude that outpatient epidoxorubicin and docetaxel plus trastuzumab are safe in the neoadjuvant treatment of patients suffering from breast cancer, based on a favorable side-effect and activity profile. Thus, this regimen can be considered for further clinical trials.
PURPOSE: Combining anthracyclines and taxanes are to date the most active cytotoxic treatment option in the neoadjuvant and palliative therapy of breast cancerpatients. Adding trastuzumab to these cytotoxic agents can improve outcome for women with humanepidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. We conducted a pilot study of preoperative epidoxorubicin and docetaxel plus trastuzumab in outpatientpatients suffering from breast cancer. PATIENTS AND METHODS: Fourteen consecutive patients were enrolled in this prospective clinical pilot trial. Preoperative treatment consisted of weekly trastuzumab (4 mg/kg body-weight loading dose, 2 mg/kg/week maintenance dose), in combination with weekly epidoxorubicin (30 mg/m2 body surface area [BSA]) and docetaxel (35 mg/m2 BSA) once a week for 6 weeks followed by 1 week off therapy. RESULTS:Patients received a total of 30 cycles (median: 2 cycles, range: 2-3 cycles) of this therapeutic regimen. Outpatientepidoxorubicin and docetaxel plus trastuzumab were well tolerated. A major response to this preoperative therapy regimen could be demonstrated in 12 of 14 patients (86%) leading to breast-conserving surgery in 11 of 14 patients (79%). CONCLUSIONS: We conclude that outpatientepidoxorubicin and docetaxel plus trastuzumab are safe in the neoadjuvant treatment of patients suffering from breast cancer, based on a favorable side-effect and activity profile. Thus, this regimen can be considered for further clinical trials.
Authors: A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Catharina Wenzel; Gottfried J Locker; Manuela Schmidinger; Margarethe Rudas; Susanne Taucher; Michael F X Gnant; Raimund Jakesz; Guenther G Steger Journal: Anticancer Drugs Date: 2002-01 Impact factor: 2.248
Authors: B Fisher; A Brown; E Mamounas; S Wieand; A Robidoux; R G Margolese; A B Cruz; E R Fisher; D L Wickerham; N Wolmark; A DeCillis; J L Hoehn; A W Lees; N V Dimitrov Journal: J Clin Oncol Date: 1997-07 Impact factor: 44.544
Authors: S M Scholl; A Fourquet; B Asselain; J Y Pierga; J R Vilcoq; J C Durand; T Dorval; T Palangié; M Jouve; P Beuzeboc Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: A Gennari; B Salvadori; S Donati; C Bengala; C Orlandini; R Danesi; M Del Tacca; P Bruzzi; P F Conte Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: C Pazos; E Mickiewicz; M R Di Notto; F Cóppola; M Ventriglia; S Jovtis; L Balbiani; D Lewi; M Róndinón; G Témperley; M Trigo; A M Bertoncín; M Pascual; G Uranga; E Cazap; S Breier; S Grasso; R Estévez; E Triguboff; A Alvarez; A Suárez Journal: Breast Cancer Res Treat Date: 1999-05 Impact factor: 4.872
Authors: Catharina Wenzel; Gottfried J Locker; Ursula Pluschnig; Christoph C Zielinski; Margarethe Rudas; Gerhard Oberhuber; Michael F Gnant; Susanne Taucher; Raimund Jakesz; Guenther G Steger Journal: Cancer Chemother Pharmacol Date: 2002-06-07 Impact factor: 3.333
Authors: A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544
Authors: V Dieras; B Chevallier; P Kerbrat; I Krakowski; H Roche; J L Misset; M A Lentz; N Azli; M Murawsky; A Riva; P Pouillart; P Fumoleau Journal: Br J Cancer Date: 1996-08 Impact factor: 7.640
Authors: David Sarid; Ilan G Ron; Fani Sperber; Yona Stadler; Perry Kahan; Felix Kovner; Rami Ben-Yosef; Sylvia Marmor; Yulia Grinberg; Natalie Maimon; Juliana Weinstein; Neora Yaal-Hahoshen Journal: Clin Drug Investig Date: 2006 Impact factor: 2.859
Authors: F Peintinger; A U Buzdar; H M Kuerer; J A Mejia; C Hatzis; A M Gonzalez-Angulo; L Pusztai; F J Esteva; S S Dawood; M C Green; G N Hortobagyi; W F Symmans Journal: Ann Oncol Date: 2008-07-29 Impact factor: 32.976
Authors: Katharina Pachmann; Oumar Camara; Andreas Kavallaris; Uwe Schneider; Stefanie Schünemann; Klaus Höffken Journal: Breast Cancer Res Date: 2005-10-04 Impact factor: 6.466